Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Abstract

Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge, as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and the encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer, presents novel nanomedicine therapeutics aimed at improving the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for the clinical application of nanomedicine in the management of LC resistance.

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

“…The inhibition of cancer cell proliferation is a multifactorial process that might occur due to the accumulation/efflux of the cytotoxic agent and the genetic makeup of the cancer cells, among other factors [ 74 , 75 ]. The results indicate that the observed time-dependent decrease in cell viability could be due to an increase in the cellular uptake of DOX released from DOX/opt CH after prolonged exposure.…”

Responsive Nanomaterial Delivery Systems for Pancreatic Cancer Management

“…[28] Lipid/RNA NPs have shown the effectiveness of medical nanomaterials during the ongoing SARS-CoV-2 pandemic, [29] and further development of NPs as drug delivery vehicles continue to address challenges associated with many therapeutic agents, such as poor aqueous solubility, unfavorable pharmacokinetics, toxicity concerns and limited stability. [30] The past two decades have witnessed significant progress in cancer pathology and nanoscience, resulting in the development of numerous nanomaterials for cancer treatment and diagnosis. [31] Given their distinct features, such as large surface area to volume ratio, availability in numerous morphologies and physical forms, and accessible surface functionality, synthetic nanomaterials are promising candidates for pancreatic cancer therapeutics.…”

Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs

“…For example, the “needle-like” shape of CNTs, coupled with a high aspect ratio (length-to-width ratio), hydrophobicity, and bio-persistence, has raised concerns about lung toxicity [ 27 ]. However, this type of nanodrug can be a highly effective anti-lung cancer agent that specifically targets lung tumors because it selectively accumulates in lung tumor tissues [ 28 ].…”